Amplifying the Voice of the Patient in Clinical Research: Development of Toolkits for Use in Designing and Conducting Patient-Centered Clinical Studies.

Clinical research Clinical trial Participant Patient advocacy Patient engagement Patient-focused Protocol TransCelerate Biopharma Inc.

Journal

Therapeutic innovation & regulatory science
ISSN: 2168-4804
Titre abrégé: Ther Innov Regul Sci
Pays: Switzerland
ID NLM: 101597411

Informations de publication

Date de publication:
11 2020
Historique:
received: 07 05 2020
accepted: 30 05 2020
pubmed: 4 7 2020
medline: 4 6 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

Incorporating patient perspectives into clinical studies is recognized as important to the development of high-quality, safe, and effective fit-for-patient medicines. However, no widely accepted methodology to help design more patient-centered studies has been established systematically. TransCelerate Biopharma Inc., a non-profit organization promoting collaboration across biopharmaceutical companies, organized a Patient Experience (PE) Initiative to create tools to intentionally include the patient perspective into the design and implementation of clinical studies. The resulting tools include the Patient Protocol Engagement Toolkit (P-PET), to engage patients early in protocol development, and the Study Participant Feedback Questionnaire (SPFQ), to assess patient experiences during clinical studies. To develop these toolkits, TransCelerate conducted a literature review and identified aspects of clinical studies that patients find either valuable or burdensome, or that affect participation, adherence, and engagement in a clinical study. The concepts identified were refined through elicitation of feedback from patient advisors, clinical study site advisors, and subject matter experts from member companies (MCs) of TransCelerate. This feedback was considered in identifying gaps, defining scientific methodology to understand how to evaluate patients' needs, and developing and refining the P-PET and the SPFQ. As part of the development process, descriptions/drafts of the tools were shared with patients, clinical site advisory groups, MCs, and the US Food and Drug Administration, and then revised. MCs simulated use of the tools, and feedback was incorporated into the final versions of the P-PET and SPFQ prior to public release. The P-PET and SPFQ are available free on the TransCelerate website.

Identifiants

pubmed: 32617912
doi: 10.1007/s43441-020-00176-6
pii: 10.1007/s43441-020-00176-6
pmc: PMC7704503
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1489-1500

Auteurs

Mary Elmer (M)

Merck & Co., Inc., Upper Gwynedd, PA, 19446, USA.

Cathy Florek (C)

Bristol Myers Squibb, Princeton, NJ, 08540, USA.

Lori Gabryelski (L)

Merck & Co., Inc., Upper Gwynedd, PA, 19446, USA.

Alison Greene (A)

Patient-Centered Outcomes Research, Genentech, San Francisco, CA, 94080, USA.

Anne Marie Inglis (AM)

Clinical Operations, GlaxoSmithKline, 1250 South Collegeville Road, MS UP 4210, Collegeville, PA, 19426, USA.

Karen L Johnson (KL)

Merck & Co., Inc., Upper Gwynedd, PA, 19446, USA.

Tanja Keiper (T)

Global Clinical Operations, EMD Serono/Merck Healthcare KGaA, 64293, Darmstadt, Germany.

Sean Ludlam (S)

Clinical Records Management, Allergan, Madison, NJ, 07940, USA.

T J Sharpe (TJ)

Patient Advisor, Starfish Harbor, Fort Lauderdale, FL, 33316, USA.

Kathyjo Shay (K)

Clinical Science Center of Excellence, Astellas Pharma Global Development, Inc., Northbrook, IL, 60062, USA. Kathyjo.Shay@astellas.com.

Fabian Somers (F)

Clinical Development, UCB Pharma, Brussels, Belgium.

Catherine Sutherland (C)

Drug Development Operations, Allergan, Buckinghamshire, SL7 1YL, UK.

Michele Teufel (M)

Development Operations, AstraZeneca, Wilmington, DE, 19850-5437, USA.

Stephen Yates (S)

Global Clinical Development, UCB Pharma, Raleigh, NC, 27617, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH